Cardiff Oncology (CRDF) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CRDF Stock Forecast

Cardiff Oncology stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CRDF Analyst Ratings

Buy

According to 2 Wall Street analysts, Cardiff Oncology's rating consensus is 'Buy'. The analyst rating breakdown for CRDF stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 06, 2024	Craig-Hallum		Buy	Initialise
Jun 05, 2022	Piper Sandler	Overweight	Overweight	Hold

Cardiff Oncology's last stock rating was published by Craig-Hallum on Sep 06, 2024. The company Initialise its CRDF rating from "null" to "Buy".

Cardiff Oncology Financial Forecast

Cardiff Oncology Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$156.00K	$141.00K	$108.00K	$83.00K	$128.00K	$93.00K	$91.00K	$74.00K	$133.00K	$86.00K	$68.00K	$72.00K	$119.25K	$136.40K
Avg Forecast	$301.30K	$287.66K	$274.64K	$262.21K	$50.00K	$50.00K	$50.00K	$50.00K	$100.00K	$100.00K	$80.00K	$80.00K	$80.00K	$70.00K	$58.75K	$62.50K	$50.00K	$50.00K	$50.00K	$65.60K	$73.25K	$68.20K	$93.00K	$56.60K	$41.00K	$40.00K	$152.50K	$152.50K	$43.33K	$50.00K
High Forecast	$494.98K	$472.58K	$451.19K	$430.77K	$82.14K	$82.14K	$82.14K	$82.14K	$164.28K	$164.28K	$131.43K	$131.43K	$125.71K	$72.50K	$58.88K	$62.75K	$62.50K	$82.14K	$82.14K	$107.77K	$120.34K	$68.20K	$93.00K	$56.60K	$41.00K	$40.00K	$152.50K	$152.50K	$43.33K	$50.00K
Low Forecast	$107.61K	$102.73K	$98.08K	$93.64K	$17.86K	$17.86K	$17.86K	$17.86K	$35.71K	$35.71K	$28.57K	$28.57K	$28.57K	$67.50K	$58.63K	$62.25K	$31.25K	$17.86K	$17.86K	$23.43K	$26.16K	$68.20K	$93.00K	$56.60K	$41.00K	$40.00K	$152.50K	$152.50K	$43.33K	$50.00K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	3	5	4	5	4	5	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.12%	2.82%	2.16%	1.27%	1.75%	1.36%	0.98%	1.31%	3.24%	2.15%	0.45%	0.47%	2.75%	2.73%

Cardiff Oncology's average Quarter revenue forecast for Mar 24 based on 1 analysts is $62.50K, with a low forecast of $62.25K, and a high forecast of $62.75K. CRDF's average Quarter revenue forecast represents a -59.94% decrease compared to the company's last Quarter revenue of $156.00K (Dec 23).

Cardiff Oncology EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	3	5	4	5	4	5	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-6.71M	$-10.82M	$-12.21M	$-11.96M	$-9.31M	$-8.91M	$-10.40M	$-11.04M	$-9.25M	$-6.73M	$-6.58M	$-5.00M	$-6.46M	$-4.37M
Avg Forecast	$-301.30K	$-287.66K	$-274.64K	$-262.21K	$-50.00K	$-50.00K	$-50.00K	$-50.00K	$-100.00K	$-100.00K	$-80.00K	$-80.00K	$-80.00K	$-70.00K	$-58.75K	$-10.17M	$-50.00K	$-50.00K	$-50.00K	$-9.25M	$-6.64M	$-68.20K	$-93.00K	$-9.89M	$-41.00K	$-40.00K	$-152.50K	$-5.40M	$-43.33K	$-50.00K
High Forecast	$-107.61K	$-102.73K	$-98.08K	$-93.64K	$-17.86K	$-17.86K	$-17.86K	$-17.86K	$-35.71K	$-35.71K	$-28.57K	$-28.57K	$-28.57K	$-67.50K	$-58.63K	$-8.14M	$-31.25K	$-17.86K	$-17.86K	$-7.40M	$-5.31M	$-68.20K	$-93.00K	$-7.91M	$-41.00K	$-40.00K	$-152.50K	$-4.32M	$-43.33K	$-50.00K
Low Forecast	$-494.98K	$-472.58K	$-451.19K	$-430.77K	$-82.14K	$-82.14K	$-82.14K	$-82.14K	$-164.28K	$-164.28K	$-131.43K	$-131.43K	$-125.71K	$-72.50K	$-58.88K	$-12.21M	$-62.50K	$-82.14K	$-82.14K	$-11.10M	$-7.97M	$-68.20K	$-93.00K	$-11.87M	$-41.00K	$-40.00K	$-152.50K	$-6.48M	$-43.33K	$-50.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	134.12%	216.40%	244.16%	1.29%	1.40%	130.67%	111.88%	1.12%	225.61%	168.32%	43.13%	0.93%	149.05%	87.32%

undefined analysts predict CRDF's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cardiff Oncology's previous annual EBITDA (undefined) of $NaN.

Cardiff Oncology Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	3	5	4	5	4	5	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-10.19M	$-9.74M	$-11.16M	$-10.39M	$-8.00M	$-8.15M	$-10.19M	$-10.91M	$-9.52M	$-6.91M	$-6.76M	$-5.18M	$-6.60M	$-4.50M
Avg Forecast	$-19.34M	$-19.53M	$-18.83M	$-19.02M	$-16.41M	$-16.03M	$-14.72M	$-14.34M	$-11.78M	$-11.59M	$-11.11M	$-11.11M	$-11.51M	$-12.63M	$-11.60M	$-10.32M	$-12.52M	$-13.31M	$-12.22M	$-9.38M	$-6.72M	$-11.83M	$-11.03M	$-10.04M	$-7.70M	$-7.62M	$-6.72M	$-5.52M	$-6.28M	$-8.37M
High Forecast	$-3.18M	$-3.21M	$-3.09M	$-3.12M	$-2.70M	$-2.63M	$-2.42M	$-2.36M	$-1.93M	$-1.90M	$-1.83M	$-9.83M	$-10.18M	$-2.07M	$-1.91M	$-8.26M	$-11.55M	$-2.19M	$-2.01M	$-7.51M	$-5.38M	$-11.83M	$-11.03M	$-8.03M	$-7.70M	$-7.62M	$-6.72M	$-4.42M	$-6.28M	$-8.37M
Low Forecast	$-35.50M	$-35.85M	$-34.57M	$-34.91M	$-30.12M	$-29.43M	$-27.03M	$-26.32M	$-21.62M	$-21.27M	$-20.40M	$-12.40M	$-12.84M	$-23.18M	$-21.29M	$-12.39M	$-13.00M	$-24.44M	$-22.44M	$-11.26M	$-8.06M	$-11.83M	$-11.03M	$-12.04M	$-7.70M	$-7.62M	$-6.72M	$-6.63M	$-6.28M	$-8.37M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.81%	0.73%	0.91%	1.11%	1.19%	0.69%	0.92%	1.09%	1.24%	0.91%	1.00%	0.94%	1.05%	0.54%

Cardiff Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRDF's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cardiff Oncology SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	3	5	4	5	4	5	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.73M	$2.94M	$4.30M	$3.08M	$3.08M	$3.08M	$3.09M	$3.94M	$3.83M	$2.93M	$2.84M	$2.23M	$3.42M	$1.64M
Avg Forecast	$8.43M	$8.04M	$7.68M	$7.33M	$1.40M	$1.40M	$1.40M	$1.40M	$2.80M	$2.80M	$2.24M	$2.24M	$2.24M	$1.96M	$1.64M	$1.75M	$1.40M	$1.40M	$1.40M	$1.83M	$2.05M	$1.90M	$2.59M	$1.57M	$1.14M	$1.11M	$4.24M	$4.24M	$1.20M	$1.39M
High Forecast	$13.84M	$13.21M	$12.62M	$12.05M	$2.30M	$2.30M	$2.30M	$2.30M	$4.59M	$4.59M	$3.68M	$3.68M	$3.52M	$2.03M	$1.65M	$1.75M	$1.75M	$2.30M	$2.30M	$3.01M	$3.37M	$1.90M	$2.59M	$1.57M	$1.14M	$1.11M	$4.24M	$4.24M	$1.20M	$1.39M
Low Forecast	$3.01M	$2.87M	$2.74M	$2.62M	$499.33K	$499.33K	$499.33K	$499.33K	$998.66K	$998.66K	$798.92K	$798.92K	$798.92K	$1.89M	$1.64M	$1.74M	$873.84K	$499.33K	$499.33K	$655.11K	$731.51K	$1.90M	$2.59M	$1.57M	$1.14M	$1.11M	$4.24M	$4.24M	$1.20M	$1.39M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.95%	2.10%	3.07%	1.68%	1.50%	1.62%	1.19%	2.50%	3.36%	2.63%	0.67%	0.53%	2.84%	1.18%

Cardiff Oncology's average Quarter SG&A projection for Mar 24 is $1.75M, based on 1 Wall Street analysts, with a range of $1.74M to $1.75M. The forecast indicates a -35.87% fall compared to CRDF last annual SG&A of $2.73M (Dec 23).

Cardiff Oncology EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	3	5	4	5	4	5	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.23	$-0.22	$-0.25	$-0.23	$-0.18	$-0.19	$-0.24	$-0.25	$-0.23	$-0.17	$-0.17	$-0.14	$-0.28	$-0.19
Avg Forecast	$-0.41	$-0.42	$-0.40	$-0.41	$-0.35	$-0.34	$-0.31	$-0.31	$-0.25	$-0.25	$-0.24	$-0.24	$-0.25	$-0.27	$-0.25	$-0.25	$-0.27	$-0.28	$-0.26	$-0.23	$-0.23	$-0.26	$-0.25	$-0.23	$-0.17	$-0.17	$-0.15	$-0.15	$-0.14	$-0.19
High Forecast	$-0.07	$-0.07	$-0.07	$-0.07	$-0.06	$-0.06	$-0.05	$-0.05	$-0.04	$-0.04	$-0.04	$-0.21	$-0.22	$-0.04	$-0.04	$-0.04	$-0.25	$-0.05	$-0.04	$-0.04	$-0.04	$-0.26	$-0.25	$-0.23	$-0.17	$-0.17	$-0.15	$-0.15	$-0.14	$-0.19
Low Forecast	$-0.76	$-0.76	$-0.74	$-0.74	$-0.64	$-0.63	$-0.58	$-0.56	$-0.46	$-0.45	$-0.44	$-0.26	$-0.27	$-0.49	$-0.45	$-0.46	$-0.28	$-0.52	$-0.48	$-0.41	$-0.43	$-0.26	$-0.25	$-0.23	$-0.17	$-0.17	$-0.15	$-0.15	$-0.14	$-0.19
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.86%	0.77%	0.96%	1.02%	0.77%	0.72%	0.98%	1.07%	1.34%	1.00%	1.13%	0.95%	2.02%	1.02%

According to undefined Wall Street analysts, Cardiff Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRDF previous annual EPS of $NaN (undefined).

Cardiff Oncology Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	$0.29	$14.00	4727.59%	Buy
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
NLSP	NLS Pharmaceutics	$1.85	$6.00	224.32%	Buy
SLS	SELLAS Life Sciences Group	$0.88	$2.80	218.18%	Buy
AUTL	Autolus Therapeutics	$2.49	$7.60	205.22%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
CUE	Cue Biopharma	$1.06	$3.00	183.02%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
CRDF	Cardiff Oncology	$5.35	$7.00	30.84%	Buy
KOD	Kodiak Sciences	$8.87	$11.00	24.01%	Buy

CRDF Forecast FAQ

Is Cardiff Oncology a good buy?

Yes, according to 2 Wall Street analysts, Cardiff Oncology (CRDF) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CRDF's total ratings.

What are Cardiff Oncology's analysts' financial forecasts?

Cardiff Oncology's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $200K (high $328.57K, low $71.43K), average EBITDA is $-200K (high $-71.428K, low $-329K), average net income is $-61.506M (high $-10.104M, low $-113M), average SG&A $5.59M (high $9.19M, low $2M), and average EPS is $-1.312 (high $-0.216, low $-2.409). CRDF's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.13M (high $1.85M, low $402.07K), average EBITDA is $-1.126M (high $-402K, low $-1.85M), average net income is $-76.713M (high $-12.603M, low $-141M), average SG&A $31.48M (high $51.72M, low $11.24M), and average EPS is $-1.637 (high $-0.269, low $-3.005).

Did the CRDF's actual financial results beat the analysts' financial forecasts?

Based on Cardiff Oncology's last annual report (Dec 2023), the company's revenue was $488K, beating the average analysts forecast of $215.6K by 126.35%. Apple's EBITDA was $-45.412M, beating the average prediction of $-9.397M by 383.25%. The company's net income was $-41.465M, missing the average estimation of $-47.432M by -12.58%. Apple's SG&A was $13.04M, beating the average forecast of $6.03M by 116.35%. Lastly, the company's EPS was $-0.93, missing the average prediction of $-1.038 by -10.39%. In terms of the last quarterly report (Dec 2023), Cardiff Oncology's revenue was $156K, beating the average analysts' forecast of $50K by 212.00%. The company's EBITDA was $-6.706M, beating the average prediction of $-50K by 13312.00%. Cardiff Oncology's net income was $-10.19M, missing the average estimation of $-12.515M by -18.58%. The company's SG&A was $2.72M, beating the average forecast of $1.4M by 94.90%. Lastly, the company's EPS was $-0.23, missing the average prediction of $-0.267 by -13.87%